Last updated September 2026 · How we research
Oral GLP-1 pill cost in 2026: Wegovy vs. Foundayo
Two oral GLP-1 pills are approved and self-pay priced in the US in 2026: Novo Nordisk's oral Wegovy (semaglutide) and Eli Lilly's Foundayo (orforglipron). Both start at $149 a month at their lowest self-pay dose and top out at $299 to $349 at the highest doses, well under list price. Oral Wegovy posted a stronger weight loss number in its approval trial, 16.6% versus Foundayo's 12.4%, but Foundayo skips the fasting rule oral semaglutide still requires. Both now qualify for a $50/month Medicare copay. Here is what actually separates them on cost, effectiveness, and daily routine.
How much does the oral Wegovy pill cost in 2026?
Novo Nordisk sells oral Wegovy through its own NovoCare Pharmacy self-pay program rather than relying on insurance approval. The price climbs with dose but not smoothly: $149 a month at the 1.5mg starting tablet, $199 at 4mg, then $299 a month at both the 9mg dose and the top 25mg dose patients typically reach for full effect. Without any self-pay discount, the list price runs about $1,349 for a one-month supply. There is no compounded version of the pill. Compounding rules that made injectable semaglutide available at $150-$300 a month during the 2022-2024 shortage never applied to the oral formulation, so the NovoCare self-pay tier is the realistic low-cost option for most people who want the pill specifically.
| Dose | Self-Pay Cost | Notes |
|---|---|---|
| 1.5mg | $149/mo | Starting dose, NovoCare self-pay |
| 4mg | $199/mo | Second titration step |
| 9mg, 25mg | $299/mo | Maintenance doses; price does not rise further at 25mg |
| List price, any dose | ~$1,349/mo | No self-pay or insurance discount |
| Compounded oral semaglutide | Not available | Oral formulation is not compounded |
NovoCare pricing current as of the 2026 Wegovy pill price guide. Verify current rates directly with NovoCare before enrolling.
How much does Foundayo (orforglipron) cost?
Foundayo, Eli Lilly's brand name for orforglipron, launched with its own LillyDirect self-pay tier after FDA approval on April 1, 2026. Self-pay pricing starts at $149 a month at the 0.8mg starting dose, $199 at 2.5mg, and $299 a month from 5.5mg through 17.2mg. At the top two doses, 14.5mg and 17.2mg, that $299 rate holds only if you refill within 45 days of your last order; miss that window and the price rises to $349. Eligible Medicare beneficiaries pay less than any self-pay tier: the Medicare GLP-1 Bridge, a CMS demonstration program that started July 1, 2026 and runs through the end of 2027, caps the copay for Foundayo and oral Wegovy alike at $50 a month for patients with obesity or a qualifying weight-related condition, once a doctor files the prior authorization.
| Dose | Self-Pay Cost | Notes |
|---|---|---|
| 0.8mg | $149/mo | Starting dose |
| 2.5mg | $199/mo | Second titration step |
| 5.5mg, 9mg | $299/mo | No refill deadline at these doses |
| 14.5mg, 17.2mg | $299/mo | Requires refill within 45 days of last order |
| 14.5mg, 17.2mg (late refill) | $349/mo | Standard price outside the 45-day window |
| Medicare GLP-1 Bridge | $50/mo | Eligible patients, July 2026-Dec 2027, PA required |
LillyDirect pricing current as of Foundayo's 2026 coverage and savings terms. Verify current rates directly with LillyDirect before enrolling.
Oral Wegovy vs. Foundayo: which pill works better?
Oral Wegovy posted the stronger number in its own approval trial. OASIS 4 found a mean 16.6% body weight loss on the 25mg dose, with one in three participants losing 20% or more. Foundayo's ATTAIN-1 trial found adults on the highest 36mg dose lost an average of 27.3 pounds, or 12.4% of body weight, over 72 weeks, against 2.2 pounds (0.9%) on placebo. The two drugs were never tested head-to-head, so that gap is not a controlled comparison, but it is the best data either company has published. The daily-routine difference cuts the other way: oral Wegovy has to be taken on an empty stomach with no more than 4 ounces of water and a 30-minute wait before eating or drinking anything else, because its bioavailability without that window is only about 1%. Foundayo is a small molecule rather than a peptide, so it survives digestion without a special formulation and carries no fasting requirement at all. For the full side-by-side on dosing, tolerability, and switching between the two, see the oral semaglutide vs. orforglipron comparison.
| Oral Wegovy | Foundayo | |
|---|---|---|
| Active drug class | Peptide (semaglutide) | Small molecule (orforglipron) |
| Weight loss (trial) | 16.6% mean (OASIS 4) | 12.4% at 36mg (ATTAIN-1) |
| Fasting required | 30 min, empty stomach, ≤4 oz water | No |
| FDA approval date | December 22, 2025 | April 1, 2026 |
| Self-pay range | $149-$299/mo | $149-$349/mo |
| Medicare Bridge copay | $50/mo (eligible) | $50/mo (eligible) |
What should decide which pill you pick?
- Whether you can keep the fasting window
- If a 30-minute empty-stomach routine every morning is not realistic for you, Foundayo removes that requirement entirely. If you already take other pills that way, oral Wegovy is not a hard change.
- Medicare eligibility
- If you qualify for the Medicare GLP-1 Bridge, both pills cost the same $50 a month, so the fasting requirement and dose availability matter more than price.
- Dose you actually need
- Oral Wegovy's jump from $149 to $299 happens between the 4mg and 9mg doses. Foundayo's pricing scales in three steps up to $349. Ask what dose you are likely to titrate to before comparing sticker prices.
- Injectable is still an option
- Both weekly injections remain modestly more effective than either pill and, where compounding is still legal, can cost less. The pill is the better real-world choice mainly for people who will not stick with a needle.
What other oral GLP-1 pills are coming?
Three more oral candidates are behind Foundayo and oral Wegovy in the pipeline. Aleniglipron, from Structure Therapeutics, posted 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2, the highest figure reported at that stage among oral GLP-1 drugs, with a Phase 3 program slated to begin in Q3 2026. See what is aleniglipron for the trial breakdown. CX11, from Corxel Pharmaceuticals, reported 11.5% weight loss at 36 weeks in a June 2026 Phase 2 readout, with global Phase 3 not targeted until early 2027; details at what is CX11. KAI-7535 (HRS-7535) posted Phase 3 results out of China of up to 10.9-11.1% weight loss, with roughly double the nausea and vomiting rates of CX11 and orforglipron; see what is KAI-7535 for the tolerability data. None of the three has US self-pay pricing yet.
Looking for the cheapest option?
Both oral pills start at $149 a month self-pay, or $50 a month if you qualify for the Medicare GLP-1 Bridge.
Frequently Asked Questions
Sources
- Wegovy pill price guide, self-pay pricing by dose, NovoCare
- Foundayo (orforglipron) self-pay pricing by dose, breakdown of the LillyDirect terms
- FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss with no food or water restrictions
- CMS: Medicare GLP-1 Bridge, official program page
- FDA approves oral Wegovy pill: OASIS 4 trial results and approval date, Novo Nordisk
Related: Semaglutide online cost
Related: Oral semaglutide vs orforglipron, in depth
Related: Foundayo UK approval: what it means for the US
Related: Tirzepatide online cost
